Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis sales and earnings

This article was originally published in The Tan Sheet

Executive Summary

Novartis' health care portfolio helps it achieve a record $39.8 billion in net sales in 2007, an 8 perent increase, the firm announced Jan. 17. Novartis attributes its success in part to its OTC and animal health performance - despite a weak cough and cold season in the U.S. - because of renewed focus on strategic brands, new product launches and expansions. Novartis' operating income also went up 15 percent to $85 million for consumer health continuing operations thanks to a better product mix and a reduction in operation costs, the Swiss firm says in a statement. Fourth quarter net sales grew 6 percent to $9.93 billion Consumer Health grew 14 percent to $1.41 billion, helping to offsest "negative developments in Pharmaceuticals in the U.S. and a weaker quarter in Vaccines and Diagnostics" that contributed to net income of $931 million, a 42 percent decrease from the prior-year quarter...

You may also be interested in...

US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump

Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.

Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy

Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.

Execs On The Move: New CFOs At Pacific Biosciences, Aziyo Biologics; Illumina Gets Marketing Boss

Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts